Clinical Trials
4 trialsNCT06038526 2026-05-20
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04789681 2026-04-16
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05725343 2023-02-13
CANAL
Mario Negri Institute for Pharmacological Research
Phase 3 Terminated
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed